NYSE: RYAMRayonier Advanced Materials Inc Stock
$7.20-0.14 (-1.91%)
Updated Oct 27, 2025
RYAM Price
$7.20
Fair Value Price
N/A
Market Cap
$482.41M
52 Week Low
$3.35
52 Week High
$10.28
P/E
-1.08x
P/B
1.41x
P/S
0.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.52B
Earnings
-$443.73M
Gross Margin
8.4%
Operating Margin
-1.77%
Profit Margin
-29.2%
Debt to Equity
4.13
Operating Cash Flow
$114M
Beta
1.47
Next Earnings
Nov 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RYAM Overview
Rayonier Advanced Materials Incorporated is a chemical company that specializes in cellulose-based technologies, including high purity cellulose specialties, a natural polymer commonly found in filters, food, pharmaceuticals and other industrial applications. The company produces lightweight paperboard and a bulky, high-yield pulp for use in consumer products. It also produces a variety of chemical treatments to provide customized product functionality. Rayonier Advanced Materials was founded in 1926 and is headquartered in Jacksonville, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RYAM's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Chemical
Industry Rating
F
RYAM
Ranked#10 of 14
Ranked#10 of 14
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $19.63 | B | |
| $31.79 | C | |
| $19.75 | C |
Be the first to know about important RYAM news, forecast changes, insider trades & much more!
RYAM News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RYAM scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RYAM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RYAM is poor value based on its book value relative to its share price (1.41x), compared to the US Chemicals industry average (1.03x)
P/B vs Industry Valuation
RYAM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more RYAM due diligence checks available for Premium users.
Valuation
RYAM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.08x
Industry
-7.96x
Market
39.86x
RYAM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.41x
Industry
1.03x
RYAM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RYAM's financial health
Profit margin
Revenue
$340.0M
Net Income
-$363.2M
Profit Margin
-106.8%
RYAM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RYAM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.8B
Liabilities
$1.4B
Debt to equity
4.13
RYAM's short-term assets ($539.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RYAM's long-term liabilities ($1.04B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RYAM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RYAM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$30.2M
Investing
-$37.5M
Financing
$1.6M
RYAM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RYAM vs Chemical Stocks
Rayonier Advanced Materials Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.